Joining forces to harness the full potential of therapies for life-threatening diseases
Partnerships are key to fuel our quest to innovative products that will enhance our pipeline, but also to identify the right commercial partners that will help us develop and commercialize our drug candidates. Based on our experience, we understand the creativity and challenges it takes to translate innovation into products. Celyad is looking to consider all opportunities with a strong scientific rationale in the field of immune-therapy regardless of the development stage.
FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®
Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
Want to see more?